Cesca Therapeutics Inc (KOOL) Receives Average Rating of “Strong Buy” from Analysts
Shares of Cesca Therapeutics Inc (NASDAQ:KOOL) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus price target of $1.50 for the company and are forecasting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also given Cesca Therapeutics an industry rank of 88 out of 257 based on the ratings given to its competitors.
Separately, Zacks Investment Research lowered Cesca Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 18th.
Cesca Therapeutics (NASDAQ:KOOL) last released its quarterly earnings results on Monday, August 13th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.16. Cesca Therapeutics had a negative return on equity of 18.05% and a negative net margin of 322.75%. The business had revenue of $2.00 million during the quarter, compared to analyst estimates of $3.00 million. Equities analysts predict that Cesca Therapeutics will post 0.1 earnings per share for the current year.
About Cesca Therapeutics
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.
See Also: Preferred Stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.